Navigation Links
GLEEVEC - An Oral treatment for leukemia

The U.S.Food and Drug Administration (FDA) at a conference in Washington, approves the new leukemia drug-GLEEVEC, first of its kind that directly removes the sign of a protein known to cause cancer. It is given as an oral treatment for chronic myelogenous leukemia (CML). Other molecular-targeting drugs previously approved by the FDA interfere with proteins associated with other cancers, but not with proteins that directly cause the disease.

Gleevec, was discovered and developed by Novartis Oncology in collaboration with its colleagues. CML is a disease in which too many white blood cells are produced in the bone marrow. In the early stages of CML, most patients do not have any symptoms of cancer,but the disease progresses slowly.

In the chronic phase, bone marrow transplantation is the only known cure. But there are many problems and side effects regarding the tranplantation which makes it more difficult to perform.

Gleevec has produced higher remission rates in comparison to the drug-interferon alfa, in three short-duration, early phase clinical trials.After many clinical trials - the FDA approved Gleevec.

Richard Klausner, M.D., director of the National Cancer Institute, said that he shared in the excitement of people with CML, but he also mentioned several caveats. He said many research questions remain to be answered, such as how long Gleevec will control CML. Does the drug actually cure CML patients? Or, does it delay the onset of moreadvanced forms of the cancer?

According to Klausner, "Gleevec offers proof that molecular targeting works in treating cancer, provided that the target is correctly chosen. The challenge now is to find these targets."

Courtesy: Novartis Oncology
'"/>




Page: 1

Related medicine news :

1. GLEEVEC - An Oral treatment for leukemia
2. Thyroid hormone treatment hastens recovery after cardiac surgery
3. Feeding channel created by malaria parasite - a new target for malaria treatments
4. Now umbilical cord helps in stroke treatment.
5. Now AIDS treatment comes dirt-cheap
6. Breast cancer treatment to be determined by gene test
7. Hemopurifier may revolutionise AIDS treatment
8. New drug helps boost cancer treatment
9. Antidepressants come in handy for patients on treatment for hepatitis, cancers and multiple sclerosis
10. Experimental treatment for Ebola Virus Shows promising results in mice
11. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/5/2016)... ... May 05, 2016 , ... United Benefit Advisors (UBA), ... as the latest addition to its family of Partner Firms. Headquartered in Mount ... wellness, human resources, and health care consumerism specialists. , “Partnering with UBA will ...
(Date:5/5/2016)... ... May 05, 2016 , ... An essential ... U.S. states and certain Canadian provinces is now available from the International Association ... (WCRI). , The report, Workers’ Compensation Laws as of January 1, ...
(Date:5/5/2016)... Chicago, IL (PRWEB) , ... May 05, 2016 , ... ... that employers continue to face challenges in getting employees to understand and use the ... (ACA). One of the nation’s leading non-profit business groups of large, self-insured public and ...
(Date:5/5/2016)... ... May 05, 2016 , ... Vitenas Cosmetic Surgery has been ... presented by the American Institute of Architects and the Academy of Architecture for Health. ... Perkins+Will and Harrell Architects, opened to patients in October of 2014. ...
(Date:5/5/2016)... ... 2016 , ... TIME for Kids and The ZAC Foundation – a national ... reach nearly 1 million children with important water safety messages before summer break begins. ... of accidental death in children one to 6 years of age. TIME for ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... DUBLIN , May 5, 2016 /PRNewswire/ ... the addition of the  "Europe Systemic Lupus ... 2016"  report to their offering.  ... The latest research Europe Systemic Lupus ... 2016, provides comprehensive insights into Systemic Lupus ...
(Date:5/4/2016)... Israel , May 4, 2016 ... BiondVax,s CEO, Dr. Ron Babecoff , will be attending ... York City . On Thursday, May 5, ... a conference presented by Joseph Gunner & Co, ... The BiondVax presentation that Dr. Babecoff will be using is ...
(Date:5/4/2016)... , May 4, 2016 Valeritas ... of an alternative public offering (APO). This was accomplished ... company, Valeritas, Inc. and a private placement of approximately ... $5.00 per share. Under the terms of ... 2016, Valeritas Holdings, Inc. will trade on the OTC ...
Breaking Medicine Technology: